https://www.selleckchem.com/pr....oducts/geneticin-g41
Some clinical trials are ongoing in patients with FLT3-mutated AML at various treatment stages, such as induction therapy, maintenance therapy, and treatment after hematopoietic stem cell transplantation. In conclusion, in vitro, in vivo, and clinical data indicate that gilteritinib fumarate is an effective treatment option in adult patients with relapsed or refractory FLT3-mutated AML in Japan.In recent years, the success rate of drug development has declined, and along with it, RD costs have continued to rise. The
Like
Comment
Share
